Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors
المؤلفون المشاركون
Bachuwa, Ghassan
Kunwor, Ranju
Al Hadidi, Samer
Badami, Sunil
Upadhaya, Sunil
Velagapudi, Ravi Kanth
Mikkilineni, Pushyami
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-13، 13ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-07-17
دولة النشر
مصر
عدد الصفحات
13
التخصصات الرئيسية
الملخص EN
Background.
We performed meta-analysis to gather more evidence regarding clinical-molecular subgroups associated with better overall survival (OS) in advanced melanoma treated with checkpoint inhibitors.
Materials and Methods.
We performed a systematic search of PubMed, Scopus, Cochrane Library, and clinical trial.gov.
Randomized clinical trials that compared a checkpoint inhibitor (nivolumab or pembrolizumab) with investigator choice chemotherapy or ipilimumab were included in our study.
Hazard ratios (HR) and confidence interval (CI) were calculated for progression-free survival (PFS) and OS for each subgroup using generic inverse model along with the random effect method.
Results.
A total of 6 clinical trials were eligible for the meta-analysis.
OS was prolonged in wild BRAF subgroup (HR 0.65, 95% CI 0.49-0.85, p 0.002), Programmed cell death subgroup (PD-1+) (HR 0.57, 95% CI 0.41-0.80, p 0.001), and high lactate dehydrogenase (LDH) level subgroup (HR 0.60, 95% CI 0.38-0.95, p 0.03).
Similarly, we found increased OS in eastern cooperative oncology group (ECOG) 1, males and age >65 years subgroups.
Conclusions.
Checkpoint inhibitors significantly increased OS in patients with wild BRAF, positive PD-1, and high LDH.
However, results should be interpreted keeping in mind associated significant heterogeneity.
The results of this study should help in designing future clinical trials.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Badami, Sunil& Upadhaya, Sunil& Velagapudi, Ravi Kanth& Mikkilineni, Pushyami& Kunwor, Ranju& Al Hadidi, Samer…[et al.]. 2018. Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. Journal of Oncology،Vol. 2018, no. 2018, pp.1-13.
https://search.emarefa.net/detail/BIM-1195822
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Badami, Sunil…[et al.]. Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. Journal of Oncology No. 2018 (2018), pp.1-13.
https://search.emarefa.net/detail/BIM-1195822
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Badami, Sunil& Upadhaya, Sunil& Velagapudi, Ravi Kanth& Mikkilineni, Pushyami& Kunwor, Ranju& Al Hadidi, Samer…[et al.]. Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. Journal of Oncology. 2018. Vol. 2018, no. 2018, pp.1-13.
https://search.emarefa.net/detail/BIM-1195822
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1195822
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر